Breakthrough T1D, the diabetes charity, has launched an ambitious new 10-year strategy aimed at driving significant advancements in Type 1 diabetes (T1D) research, treatment, and care.
This new roadmap outlines how the charity plans to transform the lives of everyone living with T1D, offering hope for a future with more effective treatment options and the opportunity for people to choose the care that works best for them.
T1D care is evolving rapidly, with advances in disease-modifying and cellular therapies poised to transform treatment. Disease-modifying therapies, such as teplizumab, now have the potential to transform the landscape of T1D treatment by delaying the onset of symptomatic disease and altering its course. At the same time, improvements in early detection are enabling timely interventions, while wider access to new technologies like hybrid closed loop are improving day to day life by bringing a degree of automation to people’s treatment.
Breakthrough T1D’s new 10-year strategy plans to build on this progress by driving faster, bolder research by investing in innovative global research and advocating for faster access to life-changing technologies, expanding treatment options, and ongoing support. The strategy also stresses the charity’s intention to work hand-in-hand with the T1D community, ensuring that the voices and experiences of people living with the condition shape every aspect of research, policy, and care.
Karen Addington, CEO of Breakthrough T1D says: “We’re not just aiming to improve treatment. We’re committed to radically transforming the future of T1D care. At the heart of our 10-year strategy is a continued commitment to the T1D community. By working closely with people affected, we will ensure their voices shape the future of research, treatment, and care, giving hope for a world where T1D is no longer a daily struggle, but a condition we can prevent, manage, and ultimately cure.”
To achieve these ambitions, Breakthrough T1D plans to deepen its engagement with supporters, partners, and the wider T1D community to secure the critical funding needed to fuel progress. This means recruiting more supporters, inspiring new advocates, and creating stronger collaborations with researchers, healthcare providers, and industry leaders.
